Kymera Therapeutics, Inc. (KYMR) Reports Q2 Loss, Tops Revenue Estimates

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of$ 0.69. This compares to loss of $0.67 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 15.94%. A quarter ago, it was expected that this company would post a loss of$ 0.73 per share when it actually produced a loss of $0.69, delivering a surprise of 5.48%. Over the last four quarters, the company h ...